Latest Breaking News On - Jordana holovach - Page 1 : comparemela.com

Myrtelle Inc : Myrtelle s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Innovative Licensing and Access Pathway Designation from the UK Medicines and Healthcare Products Regulatory Agency

Myrtelle Inc., ("Myrtelle" or the "Company"), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the Medicines

United kingdomNancy barone kribbsJordana holovachMyrtelle incHead of communicationsEuropean medicines agencyGlobal regulatory affairs at myrtelleHealthcare products regulatory agencyPfizer incInnovative licensingAccess pathwayMarketing authorization applicationSenior vice presidentGlobal regulatory affairsN acetylaspartic acidOrphan drug

Myrtelle Announces Positive Interim Data in Phase 1/2 Clinical Trial of Its Proprietary Investigational Gene Therapy rAAV-Olig001-ASPA in Canavan Disease

Myrtelle Announces Positive Interim Data in Phase 1/2 Clinical Trial of Its Proprietary Investigational Gene Therapy rAAV-Olig001-ASPA in Canavan Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJordana holovachRob loberHead of communicationsPfizer incDrug administrationEuropean medicines agencyMyrtelle incWall streetDayton childrenGross motor function measureMullen scalesEarly learningPrincipal investigatorAttending neurosurgeonAssociate professor

Myrtelle Inc : Myrtelle s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Advanced Therapy Medicinal Product Classification from the European Medicines Agency

Myrtelle Inc., ("Myrtelle" or the "Company"), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the European

Jordana holovachKostenloser wertpapierhandelNancy barone kribbsHead of communicationsCommittee for advanced therapiesPfizer incEuropean medicines agencyGlobal regulatory affairs at myrtelleMyrtelle incAdvanced therapy medicinal productGene therapy medicinal productAdvanced therapiesCentralized procedureScientific adviceN acetylaspartic acidRare pediatric disease

Myrtelle Inc : Myrtelle Announces Positive Preliminary Clinical Data for Its Proprietary Gene Therapy in Canavan Disease

Myrtelle's Phase 1/2 clinical trial introduces first-of-its-kind proprietary recombinant adeno-associated virus (rAAV) vector designed to enable targeting of oligodendrocytes To date, 3 patients received

United statesJordana holovachArmen asatryanKostenloser wertpapierhandelChristopher jansonHead of communicationsPfizer incData monitoring committeeMyrtelle incDayton childrenGross motor function measurementMullen scalesEarly learningPrincipal investigatorAssistant professorWright state university boonshoft school

Myrtelle Announces Successful Completion of Initial Stage of Phase 1/2 Clinical Trial of Proprietary Gene Therapy for Canavan Disease and Expands Treatment to Younger Patients

Myrtelle Announces Successful Completion of Initial Stage of Phase 1/2 Clinical Trial of Proprietary Gene Therapy for Canavan Disease and Expands Treatment to Younger Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jordana holovachArmen asatryanPaola leoneHead of communicationsPfizer incData monitoring committeeMyrtelle incMonitoring committeeFirst in human phaseDayton childrenChief medical officerN acetylaspartic acidCell biologyGene therapy centerRowan university schoolOsteopathic medicine